Home › Medical › Cannabis and Menopause Symptoms
⚐ Flag an error How this page was made
Also known as: cannabis for menopausal symptoms · THC menopause · CBD menopause · marijuana and perimenopause

Cannabis and Menopause Symptoms

Separating plausible use from proven benefit in a symptom cluster with almost no rigorous trials.

Automated fact-check pass
15 cited sources
Published
Last reviewed
How this page was made

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

↯ The honest take

Cannabis use for menopause is common—roughly 1 in 4 midlife women cannabis users report trying it for this—but almost entirely unstudied as a primary treatment. The general cannabis-and-anxiety and cannabis-and-sleep literature doesn't directly apply to menopausal women, who face distinct hormonal drivers and competing health risks. Standard treatments (hormone therapy, SSRIs, CBT, vaginal estrogen) have real trial evidence. Cannabis may be a reasonable adjunct if those fail, but it's not a substitute.

Not Medical Advice

This article is not medical advice. It summarizes published evidence current as of October 2026. Menopause symptoms overlap with conditions that require clinical evaluation—thyroid disease, depression, sleep apnea, cardiovascular risk changes, and bone loss. Before using cannabis for menopause or substituting it for evidence-based treatments like menopausal hormone therapy (MHT), talk to a clinician familiar with both menopause and cannabis.

Cannabis interacts with several common medications, including warfarin (blood thinner), some SSRIs and SNRIs (antidepressants), tamoxifen (breast cancer treatment), and statins [1]. If you are considering cannabis alongside any of these, discuss it with your prescriber.

Plain-Language Summary

Menopause is defined as 12 consecutive months without menstruation; perimenopause is the transition leading up to it, typically lasting 4–10 years. Common symptoms include:

Surveys in North America show that a meaningful minority of midlife women use cannabis to manage these symptoms. A 2023 survey of women veterans found approximately 27% of cannabis users reported using it for menopause symptoms [2]. A 2023 Alberta study reported similar self-medication patterns among midlife women [3].

Use is common. Rigorous evidence is not. There are no randomized controlled trials of cannabis for menopause as a primary indication. Everything below is either extrapolated from general cannabis literature or based on mechanistic plausibility.

What Probably Works

In menopausal women specifically: nothing. No data

No cannabinoid or cannabis product has reached "probably works" status for any menopause symptom in a rigorous trial. The evidence base is so thin that even weak claims require careful framing.

When researchers cite cannabis for symptom management in midlife women, they are almost always drawing on observational surveys or extrapolating from non-menopausal populations. Surveys asking "Do you use cannabis for menopause?" and "Does it help?" consistently show "yes," but surveys cannot distinguish real drug effect from placebo, sedation, mood elevation, or simple relief of anxiety [2][3]. Those are not worthless observations—they tell us what people experience—but they are not proof that cannabis treats menopause.

What Might Work (Weak Evidence)

Sleep disruption. Menopausal insomnia is driven by vasomotor symptoms, hormonal changes, anxiety, and circadian shifts. Small trials of cannabinoids (mostly nabilone, a synthetic THC analog, and CBD) in other populations—chronic pain, PTSD, insomnia disorder—show modest improvements in sleep onset and subjective sleep quality Weak / limited [4][5]. Whether this translates to menopausal sleep specifically is unstudied. An important caveat: tolerance to THC's sedative effect develops quickly, often within weeks of regular use [5]. Sleep benefit fades even as use continues.

Anxiety and mood. CBD has shown anxiolytic (anxiety-reducing) effects in laboratory-induced anxiety tasks and small trials in social anxiety disorder Weak / limited [6]. Perimenopausal mood symptoms—including anxiety, panic-like feelings, and low mood—have distinct hormonal drivers (estrogen withdrawal, progesterone changes). No controlled trial has tested whether CBD helps menopausal anxiety specifically. THC's effects on mood in menopausal women are unknown and potentially risky; in younger populations, THC use is associated with higher rates of anxiety disorders and psychotic symptoms, particularly at high doses [7].

Joint and muscle pain. Midlife joint pain is common and often underrecognized as part of the menopause transition. Cannabis shows weak-to-moderate effects in chronic non-cancer pain in general Weak / limited [8]. Topical CBD products for joint pain are widely marketed but have minimal controlled evidence supporting efficacy. Systemic absorption of topical CBD is poor [9], making it unclear whether joint effects are pharmacological or partly placebo.

Endocannabinoid system and estrogen. Estrogen modulates tone in the endocannabinoid system, and CB1 and CB2 receptors are expressed in tissues relevant to menopause (hypothalamus, immune cells, bone, vaginal tissue) Weak / limited [10]. This is mechanistic plausibility—a reason to suspect cannabis might help—not clinical proof that it does.

What Doesn't Work or Lacks Evidence

Hot flashes and night sweats. There is no good evidence that cannabis reduces the frequency or severity of vasomotor symptoms. No data In fact, THC can cause vasodilation (widening of blood vessels) and facial flushing—effects some users report as worsening hot flashes. Survey data in which women report that cannabis "helps" hot flashes is uncontrolled, confounded by sedation and mood effects, and not separable from placebo. See Cannabis and Hot Flashes for a detailed review.

Vaginal dryness and painful intercourse. Cannabis-infused suppositories, lubricants, and topical products marketed for vaginal symptoms are sold in regulated markets. There are no controlled trials of these products, and no evidence they work. No data Vaginal estrogen cream (premarin, estrace, vagifem) is the standard of care for genitourinary syndrome of menopause; it has strong evidence of benefit, minimal systemic absorption, and is safe for most women, including those taking menopausal hormone therapy [11]. It is the rational first-line choice.

Bone loss prevention. Animal studies suggest that CB2 receptor activation affects bone remodeling, raising theoretical interest in cannabinoids for osteoporosis Weak / limited. No human data support cannabis for osteoporosis prevention or treatment. Conversely, heavy chronic cannabis use has been associated with lower bone mineral density and increased fracture risk in some studies [12]. This is concerning in a population already at risk for accelerated bone loss after menopause.

"Indica vs. sativa" for symptom control. Dispensary advice that "indica" strains help sleep and "sativa" strains improve mood reflects folk taxonomy, not pharmacology. The actual cannabinoid and terpene profile (chemovar) matters far more than the historical indica/sativa distinction Disputed [13]. Strain names and labels are unreliable; products labeled identically can vary widely in cannabinoid content [14].

What We Don't Know

The knowledge gaps are large:

As of October 2026, a handful of small observational studies and one or two pilot trials are in progress, but the evidence base remains minimal. Meaningful answers will require randomized, placebo-controlled trials recruiting menopausal women specifically.

Comparison With Standard Treatments

Menopausal hormone therapy (MHT, also called HRT). MHT—combining estrogen with progestin in most cases—has the strongest evidence for relief of vasomotor symptoms, genitourinary symptoms, and bone protection in appropriately selected patients Strong evidence [11]. The 2022 position statement from the North American Menopause Society supports MHT for symptomatic women under 60 years old or within 10 years of menopause, with individualized risk assessment [11]. For most women with mild-to-moderate symptoms, MHT is the evidence-based first choice.

Non-hormonal prescription treatments with RCT support include:

Vaginal estrogen (cream, tablet, ring) for genitourinary symptoms: strong evidence, minimal systemic absorption Strong evidence [11].

Cognitive behavioral therapy (CBT) for menopausal insomnia and distress: good evidence in small RCTs; addresses sleep hygiene, thoughts, and coping strategies Strong evidence.

Cannabis: no RCT evidence for any menopause symptom. It may be a reasonable adjunct for some women in whom standard therapies are contraindicated, not tolerated, or have failed—but that is a clinical judgment call, not an evidence-based recommendation.

Risks and Practical Considerations

Cardiovascular effects. Cannabis acutely raises heart rate, can transiently elevate blood pressure, and is associated with increased risk of myocardial infarction and stroke, particularly in older or susceptible individuals Strong evidence [15]. Cardiovascular risk rises substantially after menopause due to estrogen withdrawal and aging. This is a material concern. See Cannabis and Stroke Risk for details.

Cognition. THC impairs short-term memory, executive function, and attention acutely Strong evidence. In a population already noticing cognitive changes and concerned about brain fog, THC use can be distressing or mistakenly blamed for worsening menopause symptoms.

Falls. Sedation combined with age-related balance changes and postmenopausal bone loss raises the risk of falls and fractures.

Drug interactions. CBD inhibits liver enzymes CYP2C9, CYP2C19, and CYP3A4 Strong evidence [1]. Relevant interactions include:

See Cannabis and Polypharmacy Risks for more detail.

Cannabis use disorder. Approximately 9% of cannabis users overall develop cannabis use disorder; the rate is higher with daily use Strong evidence. Dependence can involve withdrawal symptoms (irritability, insomnia, anxiety) if use is stopped abruptly.

Respiratory effects. Smoked and vaporized cannabis affect lung tissue and immune function in the respiratory tract Strong evidence. Midlife is a sensible time to avoid inhaled products, particularly if respiratory health is already a concern. See Smoking Cannabis and Lung Health.

Product quality and labeling. Unregulated CBD products frequently mislabel cannabinoid content, with some containing no CBD at all or containing undeclared THC Strong evidence [14]. If you use cannabis, prefer products from regulated markets and request a certificate of analysis from the vendor or laboratory.

Bottom Line

Cannabis use for menopause symptoms is common and mechanistically plausible for some outcomes (sleep, anxiety, pain), but almost entirely unstudied as a primary treatment in menopausal women. The general cannabis literature for anxiety, insomnia, and chronic pain does not directly apply to midlife women facing distinct hormonal and cardiometabolic risks.

If standard evidence-based options—menopausal hormone therapy, SSRIs/SNRIs, gabapentin, vaginal estrogen, CBT—are available and appropriate for you, those have real trial evidence. Cannabis may be a reasonable adjunct in the minority of cases where standard therapies fail, are contraindicated, or are not tolerated. But using cannabis as a menopause therapy specifically, rather than as a symptom-specific adjunct, is extrapolation without evidence.

The honest answer is simple: we need the trials, and they have not been done.

Sources

  1. Peer-reviewed Brown JD, Winterstein AG. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8(7): 989.
  2. Peer-reviewed Han L, et al. (2023). Cannabis use for menopause symptom management among midlife women veterans. Menopause, 30(4): 387–394.
  3. Peer-reviewed Slavin MN, et al. (2023). Cannabis use patterns among midlife women: an Alberta-based survey. Menopause, 30(10).
  4. Peer-reviewed Suraev AS, et al. (2020). Cannabinoid therapies in the management of sleep disorders: a systematic review. Sleep Medicine Reviews, 53: 101339.
  5. Peer-reviewed Babson KA, Sottile J, Morabito D. (2017). Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports, 19(4): 23.
  6. Peer-reviewed Bergamaschi MM, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6): 1219–1226.
  7. Peer-reviewed National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press.
  8. Peer-reviewed Gorzalka BB, Dang SS. (2012). Minireview: Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology, 153(3): 1016–1024.
  9. Peer-reviewed Sophocleous A, et al. (2017). Heavy Cannabis Use Is Associated With Low Bone Mineral Density and an Increased Risk of Fractures. American Journal of Medicine, 130(2): 214–221.
  10. Peer-reviewed Piomelli D, Russo EB. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1): 44–46.
  11. Peer-reviewed The 2022 Hormone Therapy Position Statement of The North American Menopause Society. (2022). Menopause, 29(7): 767–794.
  12. Peer-reviewed Page RL, et al. (2020). Medical Marijuana, Recreational Cannabis, and Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation, 142(10): e131–e152.
  13. Peer-reviewed Hasin DS, et al. (2015). Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12): 1235–1242.
  14. Peer-reviewed Bonn-Miller MO, et al. (2017). Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 318(17): 1708–1709.
  15. Peer-reviewed Cannabis withdrawal syndrome. (Referenced in multiple sources including DSM-5 and clinical literature on cessation and dependence.)

How this page was made

Generation history

Oct 30, 2026
Revision
Oct 29, 2026
Fact-check pass — raised 9 flags
Jul 26, 2026
Self-review — raised 2 flags
May 11, 2026
Fact-check pass — raised 2 flags
May 11, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.